Hyphens Pharma International Ltd.

As of June 30, 2021, Hyphens Pharma International Ltd. carries a market capitalization of 99.14M, placing it among publicly traded companies globally. Its enterprise value stands at 72.37M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Hyphens Pharma International Ltd.'s next confirmed earnings release is scheduled for March 2, 2027.

As of June 30, 2021, Hyphens Pharma International Ltd. has 300.43M shares outstanding.

These figures are as of June 30, 2021.

As of June 30, 2021, Hyphens Pharma International Ltd. maintains a current ratio of 2.18, meaning it holds 2.2x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2021.

Over the twelve months ended June 30, 2021, Hyphens Pharma International Ltd. recorded 480,000.00 in income tax expense.

As of the close on October 23, 2026, Hyphens Pharma International Ltd.'s stock has gained approximately 1.45% over the past 52 weeks. The 50-day moving average sits at 0.36, while the 200-day moving average is 0.34.

As of June 30, 2021, Hyphens Pharma International Ltd. holds 30.92M in cash and equivalents against 4.15M in total debt, resulting in a net debt position of -28.92M. Total book value stands at 49.61M, with working capital of 40.33M providing operational flexibility.

These figures cover the twelve months ended June 30, 2021.

Over the twelve months ended June 30, 2021, Hyphens Pharma International Ltd. paid dividends of 0.01 per share.